ReviewExpert review of vaccines2016
Recombinant modified vaccinia virus Ankara-based malaria vaccines.
Review in Expert review of vaccines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Protein/AS01Cell reports. Medicine · 2021Trial
- Whole genome sequencing of recombinant viruses obtained from co-infection and superinfection of Vero cells with modified vaccinia virus ankara vectored influenza vaccine and a naturally occurring cowpox virus.Frontiers in immunology · 2024Article
- Protective Immunity Induced by Immunization with Baculovirus, Virus-like Particle, and Vaccinia Virus Expressing the AMA1 ofBiomedicines · 2022Article
- Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications.Vaccines · 2022Review
- Evaluating immunogenicity of pathogen-derived T-cell epitopes to design a peptide-based smallpox vaccine.Scientific reports · 2022Article
- Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development.Microbiology spectrum · 2022Article
- Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models ofFrontiers in immunology · 2022Article
- Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations.NPJ vaccines · 2020Article
- Modified Vaccinia Virus Ankara Can Induce Optimal CD8Journal of virology · 2019Article
- Viral Replicative Capacity, Antigen Availability via Hematogenous Spread, and High TJournal of virology · 2019Article
- CD70 encoded by modified vaccinia virus Ankara enhances CD8 T-cell-dependent protective immunity in MHC class II-deficient mice.Immunology · 2018Article
- Three-dimensional culture of chicken primordial germ cells (cPGCs) in defined media containing the functional polymer FP003.PloS one · 2018Article
- Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of RecombinantInfection and immunity · 2018Article
- Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?Viruses · 2017Review
- A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2017Review
- Article
- Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.Advances in virus research · 2017Review
- Simian adenoviruses as vaccine vectors.Future virology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A safe and effective malaria vaccine is a crucial part of the roadmap to malaria elimination/eradication by the year 2050. Viral-vectored vaccines based on adenoviruses and modified vaccinia virus Ankara (MVA) expressing malaria immunogens are currently being used in heterologous prime-boost regimes in clinical trials for induction of strong antigen-specific T-cell responses and high-titer antibodies. Recombinant MVA is a safe and well-tolerated attenuated vector that has consistently shown significant boosting potential. Advances have been made in large-scale MVA manufacture as high-yield producer cell lines and high-throughput purification processes have recently been developed. This review describes the use of MVA as malaria vaccine vector in both preclinical and clinical studies in the past 5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.